IP Library Granted Patent US 7,732,605
Granted Patent B2
US 7,732,605 · App. 11/390,326 · Granted Jun 8, 2010

Synthesis of diketopiperazines

Assignee: Nereus Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,732,605
App. No.
11/390,326
Granted
Jun 8, 2010
Kind
B2
Abstract

Disclosed herein are methods for synthesizing diketopiperazines with enantiomeric excess by inducing cyclization of an α-keto acid with an acid catalyst.

Claims (14)

1. A method of preparing a compound of formula I:

comprising reacting an acid catalyst with a compound of formula II in such a manner so as to produce the compound of formula I with an enantiomeric excess greater than about 50%:

wherein:

R 1 , R 2 , and R 3 are separately selected from the group consisting of hydrogen; halogen; mono-substituted, poly-substituted or unsubstituted, straight or branched chain variants of the following residues: C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, alkoxy, acyl, arylalkyl, heteroarylalkyl, alkyloxycarbonyloxy, ester, arylalkoxy, and alkylthio; and mono-substituted, poly-substituted or unsubstituted variants of the following residues: acyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, heteroaryl, heterocycloalkyl, carbonyl, carbonylacyl, amino, aminocarbonyl, amide, aminocarbonyloxy, nitro, azido, phenyl, hydroxyl, arylthio, oxysulfonyl, carboxy, and cyano;

R 4 and R 5 are separately selected from the group consisting of hydrogen; mono -substituted, poly-substituted or unsubstituted, straight or branched chain variants of the following residues: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 2-6 heteroalkyl, C 2-6 aminoalkyl, C 2-6 haloalkyl, C 1-6 alkoxycarbonyl, aryl-C 1-6 -alkyl, and C 2-6 hydroxyalkyl; and mono-substituted, poly-substituted and unsubstituted variants of the following residues: C 3-8 cycloalkyl, —C(O)—C 5-6 aryl substituted with C 1-3 alkyl or halo, C 5-6 aryl, C 5-6 heteroaryl, C 5-6 cycloalkyl, and C 5-6 heterocycloalkyl;

any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond; and

any carbon-carbon double bond has a configuration selected from the group consisting of cis and trans.

2. The method of claim 1 , wherein the acid catalyst is selected from the group consisting of acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, and trifluoromethanesulfonic acid.

3. The method of claim 1 , wherein the enantiomeric excess is greater than about 80%.

4. The method of claim 1 , wherein the enantiomeric excess is greater than about 90%.

5. The method of claim 1 , wherein R 1 , R 2 , and R 3 are separately selected from the group consisting of hydrogen; halogen; mono-substituted, poly -substituted or unsubstituted, straight or branched chain variants of the following residues: C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, arylalkyl, and heteroarylalkyl; and mono-substituted, poly -substituted or unsubstituted variants of the following residues: cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycloalkyl.

6. The method of claim 5 , wherein R 1 , R 2 , and R 3 are separately selected from the group consisting of hydrogen; mono-substituted, poly-substituted or unsubstituted, straight or branched chain variants of the following residues: C 1 -C 24 alkyl, arylalkyl, and heteroarylalkyl; and mono-substituted, poly-substituted or unsubstituted variants of the following residues: cycloalkyl, aryl, heteroaryl, and heterocycloalkyl.

7. The method of claim 6 , wherein R 1 , R 2 , and R 3 are separately selected from the group consisting of hydrogen, methyl, methylene, and mono-substituted, poly-substituted or unsubstituted variants of the following residues:

8. The method of claim 7 , wherein the compound of formula I is selected from the group consisting of:

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2014
From: DALIAN WANCHUN BIOTECHNOLOGY CO. LTD.
To: BEYONDSPRING PHARMACEUTICALS, INC.
Reel/Frame 033519/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2013
From: DALIAN WANCHUN BIOTECHNOLOGY CO. LTD.
To: BEYONDSPRING PHARMACEUTICALS, INC.
Reel/Frame 030723/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2013
From: NEREUS PHARMACEUTICALS, INC.
To: DALIAN WANCHUN BIOTECHNOLOGY CO. LTD.
Reel/Frame 030715/0457 →
SECURITY AGREEMENT Recorded May 21, 2009
From: NEREUS PHARMACEUTICALS, INC.
To: HBM BIOVENTURES (CAYMAN) LTD.; HBM BIOCAPITAL (EUR) L.P.; HBM BIOCAPITAL (USD) L.P.; PRIVATE LIFE BIOMED AG; ALSTERTOR PRIVATE LIFE GMBH & CO. KG; ADVENT HEALTHCARE AND LIFE SCIENCES III LIMITED PARTNERSHIP; ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP; ADVENT PARTNERS HLS III LIMITED PARTNERSHIP; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; GIMV N.V.; GIMV ADVIESBEHEER LIFE SCIENCES N.V.; LOTUS BIOSCIENCE INVESTMENT HOLDS LTD; NOVARTIS BIOVENTURE FUND / NOVARTIS INTERNATIONAL AIG; HENSLER, MARY; JACOBS, ROBERT; WS INVESTMENT COMPANY; GENAVENT PARTNERS LP; ASTELLAS VENTURE FUND I LP; ROCHE FINANCE LTD; ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCADERO PARTNERS II, LLC; ALTA CALIFORNIA PARTNERS II, L.P. - NEW POOL
Reel/Frame 022719/0115 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2006
From: HAYASHI, YOSHIO
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 017812/0048 →
Continuity (3)
Provisional Application 6066633600 · Mar 29, 2005
Provisional Application 6073075900 · Oct 27, 2005
Related Publication 20060235226A1 · Oct 19, 2006